Uganda - English - National Drug Authority

egyptian international pharmaceutical industries company - hydrocortisone sodium succinate - parenteral ordinary dry vials - 100mg

Kenya - English - Pharmacy and Poisons Board

lincoln pharmaceuticals ltd c/o medox… p.o.box 52771-00200 nairobi - hydrocortisone sodium succinate for injection bp… - injection - 100 mg - stomatological preparations: corticosteroids for

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - hydrocortisone sodium succinate - powder for solution for injection - 100mg

Uganda - English - National Drug Authority

astra pharma (u) limited; astra pharma (u) limited - hydrocortisone sodium succinate - parenteral ordinary dry vials - 100mg/vial

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

brawn laboratories limited, india - hydrocortisone sodium succinate - powder for solution for injection - 100mg

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), acetic acid (unii: q40q9n063p) (acetic acid - unii:q40q9n063p) - hydrocortisone 10.4 mg in 1 ml - for the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation. hypersensitivity to hydrocortisone and acetic acid otic solution or any of the ingredients; herpes simplex, vaccinia and varicella. perforated tympanic membrane is considered a contraindication to the use of any medication in the external ear canal.

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders  primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)  congenital adrenal hyperplasia  nonsuppurative thyroiditis  hypercalcemia associated with cancer -  primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) -  congenital adrenal hyperplasia -  nonsuppurative thyroiditis -  hypercalcemia associated with cancer - rheumatic disorders  as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:  psoriatic arthritis  rheumatoid arthritis, including juvenile rheumatoid art

United States - English - NLM (National Library of Medicine)

stat rx usa llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)   congenital adrenal hyperplasia   nonsuppurative thyroiditis   hypercalcemia associated with cancer - rheumatic disorders   as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:   psoriatic arthritis   rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy):   ankylosing spondylitis   acute and subacute bursitis   acute nonspecific tenosynovitis   acute gouty arthritis   post-traumatic osteoarthritis   synovitis or osteoarthritis   epicondylitis - collagen diseases   during an exacerbation or as maintenance therapy in selected cases of:   systemic lupus erythematosus

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)   congenital adrenal hyperplasia   nonsuppurative thyroiditis   hypercalcemia associated with cancer - rheumatic disorders   as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:   psoriatic arthritis   rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy):   ankylosing spondylitis   acute and subacute bursitis   acute nonspecific tenosynovitis   acute gouty arthritis   post-traumatic osteoarthritis   synovitis or osteoarthritis   epicondylitis - collagen diseases   during an exacerbation or as maintenance therapy in selected cases of:   systemic lupus erythematosus

United States - English - NLM (National Library of Medicine)

perrigo new york inc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), iodoquinol (unii: 63w7ie88k8) (iodoquinol - unii:63w7ie88k8) - hydrocortisone 10 mg in 1 g - based on a review of a related drug by the national research council and subsequent fda classification for that drug, the indications are as follows: “possibly” effective: contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. final classification of the less-than-effective indications requires further investigation. hydrocortisone 1%−iodoquinol 1% cream is contraindicated in those patients with a history of hypersensitivity to hydrocortisone, iodoquinol or any other components of the preparation.